AR113839A1 - Antagonistas del receptor b2 de bradiquinina - Google Patents

Antagonistas del receptor b2 de bradiquinina

Info

Publication number
AR113839A1
AR113839A1 ARP180103444A ARP180103444A AR113839A1 AR 113839 A1 AR113839 A1 AR 113839A1 AR P180103444 A ARP180103444 A AR P180103444A AR P180103444 A ARP180103444 A AR P180103444A AR 113839 A1 AR113839 A1 AR 113839A1
Authority
AR
Argentina
Prior art keywords
group
independently
halogen atom
substituted
hydrogen atom
Prior art date
Application number
ARP180103444A
Other languages
English (en)
Spanish (es)
Inventor
Lars Ole Haustedt
Horst Ambrosi
- Saupe Joern Dieter
Christoph Gibson
Original Assignee
Pharvaris B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharvaris B V filed Critical Pharvaris B V
Publication of AR113839A1 publication Critical patent/AR113839A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ARP180103444A 2017-11-24 2018-11-23 Antagonistas del receptor b2 de bradiquinina AR113839A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17203675 2017-11-24

Publications (1)

Publication Number Publication Date
AR113839A1 true AR113839A1 (es) 2020-06-17

Family

ID=60473364

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180103444A AR113839A1 (es) 2017-11-24 2018-11-23 Antagonistas del receptor b2 de bradiquinina

Country Status (29)

Country Link
US (3) US10836748B2 (enExample)
EP (2) EP3998259A1 (enExample)
JP (2) JP7164619B2 (enExample)
KR (1) KR102413321B1 (enExample)
CN (1) CN111433196B (enExample)
AR (1) AR113839A1 (enExample)
AU (1) AU2018371186B2 (enExample)
BR (1) BR112020010298A2 (enExample)
CA (1) CA3082948A1 (enExample)
CY (1) CY1125348T1 (enExample)
DK (1) DK3713928T3 (enExample)
EA (1) EA202091256A1 (enExample)
ES (1) ES2908409T3 (enExample)
HR (1) HRP20220429T1 (enExample)
HU (1) HUE058217T2 (enExample)
IL (1) IL274883B2 (enExample)
LT (1) LT3713928T (enExample)
MA (1) MA50804B1 (enExample)
MX (1) MX2020005287A (enExample)
PH (1) PH12020550683A1 (enExample)
PL (1) PL3713928T3 (enExample)
PT (1) PT3713928T (enExample)
RS (1) RS63087B1 (enExample)
SG (1) SG11202004653TA (enExample)
SI (1) SI3713928T1 (enExample)
SM (1) SMT202200154T1 (enExample)
TW (1) TWI768156B (enExample)
UY (1) UY37981A (enExample)
WO (1) WO2019101906A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3713928T (lt) 2017-11-24 2022-05-10 Pharvaris Netherlands B.V. Nauji bradikinino b2 receptoriaus antagonistai
UY38707A (es) * 2019-05-23 2020-12-31 Pharvaris Gmbh Nuevos antagonistas cíclicos del receptor b2 de bradiquinina
AR118982A1 (es) * 2019-05-23 2021-11-17 Pharvaris Gmbh Antagonistas cíclicos del receptor b2 de bradiquinina
WO2022101395A1 (en) 2020-11-12 2022-05-19 Pharvaris Gmbh Prophylaxis and treatment of angioedema
MX2024001711A (es) * 2021-08-05 2024-03-05 Pharvaris Gmbh Composición lípidica para la administración oral de antagonistas del receptor de bradicinina b2.
EP4380929A1 (en) 2021-08-05 2024-06-12 Pharvaris GmbH Solid form of a bradykinin b2-receptor antagonist
IL315699A (en) 2022-03-25 2024-11-01 Pharvaris Gmbh A solid composition comprising dissolved bradykinin B2 receptor antagonists
TW202345810A (zh) 2022-03-25 2023-12-01 瑞士商帕法瑞斯有限責任公司 包含緩激肽b2受體拮抗劑之固態延長釋放組成物
EP4499100A1 (en) 2022-03-25 2025-02-05 Pharvaris GmbH Therapeutic uses of bradykinin b2-receptor antagonists

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU680870B2 (en) 1993-04-28 1997-08-14 Astellas Pharma Inc. New heterocyclic compounds
KR970707098A (ko) 1994-10-27 1997-12-01 후지야마 아키라 브라디키닌 길항제로서 피리도피리미돈, 퀴놀린 및 융합된 N-헤테로사이클(Pyridopyrimidones, quinolines and fused N-heterocycles as bradykinin antagonists)
FR2737892B1 (fr) 1995-08-17 1997-10-24 Fournier Ind & Sante Nouveaux composes de benzenesulfonamide, procede de preparation et utilisation en therapeutique
GB9602029D0 (en) 1996-02-01 1996-04-03 Fujisawa Pharmaceutical Co New heterocyclic compounds
DE19609827A1 (de) 1996-03-13 1997-09-18 Hoechst Ag Aminoalkyl- und Acylaminoalkylether, Verfahren zu deren Herstellung und ihre Verwendung als Bradykinin-Rezeptorantagonisten
DE19610784A1 (de) 1996-03-19 1997-09-25 Hoechst Ag Fluoralkyl- und Fluoralkoxysubstituierte heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung
DE19612067A1 (de) 1996-03-27 1997-10-02 Hoechst Ag Verwendung von Bradykinin-Antagonisten zur Herstellung von Arzneimitteln zur Behandlung von chronisch fibrogenetischen Lebererkrankungen und akuten Lebererkrankungen
AUPN952696A0 (en) * 1996-04-29 1996-05-23 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds
DE19712960A1 (de) 1997-03-27 1998-10-01 Hoechst Ag Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten
JP2002517461A (ja) 1998-06-08 2002-06-18 アドバンスド メディスン インコーポレーテッド ブラジキニンアンタゴニスト
WO2000023439A1 (en) 1998-10-21 2000-04-27 Fujisawa Pharmaceutical Co., Ltd. Vitreous form of known bradykinin antagonist
FR2790260B1 (fr) 1999-02-26 2001-05-04 Fournier Ind & Sante Nouveaux composes de n-(benzenesulfonamide), procede de preparation et utilisation en therapeutique
GB9913079D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
AU2001229580A1 (en) 2000-01-18 2001-08-14 Nuerogen Corporation Substituted imidazoles as selective modulators of bradykinin b2 receptors
CA2364178C (en) 2000-12-05 2006-01-10 Yasuhiro Katsu N-benzenesulfonyl l-proline compounds as bradykinin antagonists
CA2481855A1 (en) 2002-04-10 2003-10-23 Ortho-Mcneil Pharmaceutical, Inc. Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators
ITMI20021247A1 (it) 2002-06-07 2003-12-09 Menarini Ricerche Spa Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche
ITMI20041963A1 (it) 2004-10-15 2005-01-15 Luso Farmaco Inst "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche"
EP1741444A1 (en) 2005-07-05 2007-01-10 Jerini AG Kinin antagonists for treating bladder dysfunction
TWI407960B (zh) * 2007-03-23 2013-09-11 Jerini Ag 小分子緩激肽b2受體調節劑
AR073304A1 (es) * 2008-09-22 2010-10-28 Jerini Ag Moduladores del receptor de bradiquinina b2 de molecula pequena
JP2016514141A (ja) 2013-03-14 2016-05-19 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド B2−ブラジキニン受容体媒介の血管浮腫の治療方法
LT3713928T (lt) 2017-11-24 2022-05-10 Pharvaris Netherlands B.V. Nauji bradikinino b2 receptoriaus antagonistai

Also Published As

Publication number Publication date
IL274883B1 (en) 2023-07-01
PL3713928T3 (pl) 2022-07-11
HRP20220429T1 (hr) 2022-05-27
HUE058217T2 (hu) 2022-07-28
CN111433196B (zh) 2023-06-06
CA3082948A1 (en) 2019-05-31
US20210017158A1 (en) 2021-01-21
JP7164619B2 (ja) 2022-11-01
RS63087B1 (sr) 2022-04-29
US11820756B2 (en) 2023-11-21
EP3713928B1 (en) 2022-01-12
US20200255405A1 (en) 2020-08-13
PT3713928T (pt) 2022-03-08
KR102413321B1 (ko) 2022-06-24
WO2019101906A1 (en) 2019-05-31
SMT202200154T1 (it) 2022-05-12
IL274883B2 (en) 2023-11-01
PH12020550683A1 (en) 2021-03-15
MA50804B1 (fr) 2022-05-31
CY1125348T1 (el) 2024-02-16
AU2018371186A1 (en) 2020-05-28
SI3713928T1 (sl) 2022-09-30
MA50804A (fr) 2020-09-30
UY37981A (es) 2019-06-28
US10836748B2 (en) 2020-11-17
US20220135543A1 (en) 2022-05-05
NZ764304A (en) 2024-02-23
JP2023002701A (ja) 2023-01-10
IL274883A (en) 2020-07-30
SG11202004653TA (en) 2020-06-29
ES2908409T3 (es) 2022-04-29
EP3713928A1 (en) 2020-09-30
LT3713928T (lt) 2022-05-10
EA202091256A1 (ru) 2020-10-05
TWI768156B (zh) 2022-06-21
JP2021504464A (ja) 2021-02-15
US11261173B2 (en) 2022-03-01
EP3998259A1 (en) 2022-05-18
TW202017916A (zh) 2020-05-16
KR20200094174A (ko) 2020-08-06
AU2018371186B2 (en) 2022-05-12
MX2020005287A (es) 2020-08-13
DK3713928T3 (da) 2022-04-04
CN111433196A (zh) 2020-07-17
BR112020010298A2 (pt) 2020-11-17

Similar Documents

Publication Publication Date Title
AR113839A1 (es) Antagonistas del receptor b2 de bradiquinina
AR118983A1 (es) Antagonistas cíclicos del receptor b2 de bradiquinina
AR114164A1 (es) Piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
AR106605A1 (es) Oxadiazoles sustituidos para combatir hongos fitopatógenos
UY37795A (es) Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
PE20191260A1 (es) Compuestos inhibidores del vih
AR091193A1 (es) HETEROCICLOS DE 5 MIEMBROS QUE CONTIENEN NITROGENO SUSTITUIDO POR CARBOXAMIDA O SULFONAMIDA COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUERFANO RORg
AR089143A1 (es) Triazolopiridinas sustituidas con actividad inhibidora de ttk
AR094550A1 (es) Inhibidores de btk
EA201890573A1 (ru) Новые замещенные 6-6-бициклическим ароматическим кольцом аналоги нуклеозидов для применения в качестве ингибиторов prmt5
AR111983A1 (es) ANILLOS 6 - 5 FUSIONADOS COMO INHIBIDORES DE C5a
AR112216A1 (es) Derivados de azaquinolina
AR063602A1 (es) Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos.
AR094812A1 (es) Derivado de piridina monocíclico como inhibidor del fgfr
AR114828A1 (es) Compuestos de pteridinona y sus usos
AR090596A1 (es) Formulaciones farmaceuticas que comprenden antagonistas de ccr3
AR123078A1 (es) Medicamentos antiplaquetarios y usos de estos
AR094100A1 (es) DERIVADOS CARBAMATO DE CICLOHEXILO Y QUINUCLIDINILO QUE TIENEN ACTIVIDAD COMO AGONISTAS b2 ADRENERGICOS Y COMO ANTAGONISTAS MUSCARINICOS M3
AR122703A1 (es) Inhibidores de rip1k
AR097754A1 (es) Derivados sustituidos de fenilalanina
CL2018000839A1 (es) Derivados de 2-aminoquinazolina como inhibidores de la quinasa p70s6
AR098436A1 (es) Compuestos tricíclicos de piperidina
AR104749A1 (es) Imidazo[1,2-b][1,2,4]triazina sustituida, composición farmacéutica y combinación que lo comprenden, y su uso para la fabricación de un medicamento
UY38006A (es) Inhibidores de la quinasa mtor, composiciones farmacéuticas que los contienen, y al uso en terapia de tales compuestos y composiciones
AR118982A1 (es) Antagonistas cíclicos del receptor b2 de bradiquinina